Summary
This 2023 systematic review and meta-analysis examined anti-inflammatory effects of second-generation antipsychotics in schizophrenia by synthesising evidence on inflammatory biomarker responses. The authors identified substantial heterogeneity across included studies, suggesting that potential immunomodulatory benefits may be context- and population-dependent rather than universally applicable. Methodological variation across studies limits definitive clinical conclusions regarding the breadth of antipsychotic anti-inflammatory effects.
Regional applicability
The clinical findings on antipsychotic immunomodulation are likely applicable to United Kingdom psychiatric practice, though specific UK-based trials may not have been well-represented in the meta-analysis. Transferability depends on whether included studies encompassed comparable patient populations and treatment protocols to UK standard care.
Key measures
Inflammatory biomarkers (specific markers not detailed in available metadata); heterogeneity assessment across studies
Outcomes reported
The systematic review and meta-analysis synthesised evidence on inflammatory biomarker responses in schizophrenia patients treated with second-generation antipsychotics. The study examined heterogeneity in immunomodulatory effects across included trials.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.